Scancell (LON:SCLP) Trading 29.8% Higher – Still a Buy?

Scancell Holdings plc (LON:SCLP) shares traded up 29.8% during trading on Monday . The company traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). 10,537,342 shares traded hands during mid-day trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Trading Down 4.9 %

The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock has a 50 day moving average of GBX 8.51 and a 200 day moving average of GBX 10.85. The firm has a market cap of £103.47 million, a P/E ratio of -15.32 and a beta of 0.35.

Scancell (LON:SCLP) last announced its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. As a group, equities research analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.